Transmitted Drug Resistance and Molecular Epidemiology in Antiretroviral Naive HIV Type 1-Infected Patients in Rhode Island

Transmission of HIV-1 drug resistance has important clinical and epidemiological consequences including earlier treatment failure and forward transmission of resistance strains in high-risk groups. To evaluate the prevalence and molecular epidemiology of transmitted drug resistance in Rhode Island, we collected genotypic, demographic, clinical, and laboratory data from treatment-naive individuals presenting to the largest outpatient HIV clinic in the state from January 2007 to November 2007. Sequences from 35 treatment-naive individuals were available, 83% of whom were men who had sex with men (MSM). All sequences were HIV-1 subtype B. Drug resistance mutations were identified in 7/35 [20%; 95% confidence interval (CI), 0.08-0.37] patients, six of whom had K103N. Two phylogenetic transmission clusters were found, involving 17% (6/35) of individuals, three in each cluster. We did not find an association between belonging to a cluster and age, gender, AIDS-defining illness, CD4 cell count, or viral load. Drug resistance mutations were more commonly observed in transmission clusters (p = 0.08). Individuals in one cluster all had K103N and were MSM who had attended local bathhouses. Individuals forming clusters were significantly more likely to have visited a bathhouse compared to nonclusters (p = 0.02). The prevalence of transmitted drug resistance in Rhode Island is high, further justifying genotypic testing on presentation to care and prior to treatment initiation. Molecular epidemiological analysis and association of resistance with phylogenetic networks using data obtained for clinical purposes may serve as useful tools for the prevention of drug resistance transmission and for contact tracing.

[1]  J. Blair,et al.  HIV Transmission Risk at a Gay Bathhouse , 2010, Journal of sex research.

[2]  Richard D Moore,et al.  Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Kantor,et al.  Transmitted drug resistance in nonsubtype B HIV-1 infection. , 2009, HIV therapy.

[4]  G. Marks,et al.  Prevalence of unprotected anal intercourse among HIV-diagnosed MSM in the United States: a meta-analysis , 2009, AIDS.

[5]  J. H. Chen,et al.  Molecular Epidemiological Study of HIV-1 CRF01_AE Transmission in Hong Kong , 2009, Journal of acquired immune deficiency syndromes.

[6]  Bernard Hirschel,et al.  The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection , 2009, AIDS.

[7]  J. Rich,et al.  Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007. , 2009, Medicine and health, Rhode Island.

[8]  W. Borkowsky,et al.  Implementation of HIV testing at 2 New York City bathhouses: from pilot to clinical service. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Deenan Pillay,et al.  Update of the Drug Resistance Mutations in HIV-1: December 2008 , 2008 .

[10]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[11]  Michel Roger,et al.  Transmission networks of drug resistance acquired in primary/early stage HIV infection , 2008, AIDS.

[12]  C. Birch,et al.  Phylogenetic Investigation of Transmission Pathways of Drug-Resistant HIV-1 Utilizing Pol Sequences Derived From Resistance Genotyping , 2008, Journal of acquired immune deficiency syndromes.

[13]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Relf,et al.  Antiretroviral drug resistance among treatment-naïve HIV-1-infected persons in Washington, D.C. , 2008, AIDS patient care and STDs.

[15]  M. Peeters,et al.  Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. , 2008, AIDS research and human retroviruses.

[16]  A. Rambaut,et al.  Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics , 2008, PLoS medicine.

[17]  R. Valdiserri,et al.  The reemerging HIV/AIDS epidemic in men who have sex with men. , 2007, JAMA.

[18]  J. Hogan,et al.  Lower syringe sharing and re-use after syringe legalization in Rhode Island. , 2007, Drug and alcohol dependence.

[19]  J. Blair,et al.  Probability Sample Estimates of Bathhouse Sexual Risk Behavior , 2007, Journal of acquired immune deficiency syndromes.

[20]  M. Chesney,et al.  Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection , 2007, AIDS.

[21]  Michel Roger,et al.  High rates of forward transmission events after acute/early HIV-1 infection. , 2007, The Journal of infectious diseases.

[22]  T. Neilands,et al.  Bathhouse-Based Voluntary Counseling and Testing Is Feasible and Shows Preliminary Evidence of Effectiveness , 2006, Journal of acquired immune deficiency syndromes.

[23]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[24]  Martin Fisher,et al.  Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections , 2005, AIDS.

[25]  Wolfgang Preiser,et al.  Phylogenetic analysis of HIV-1 transmission: pol gene sequences are insufficient to clarify true relationships between patient isolates , 2004, AIDS.

[26]  Christopher D Pilcher,et al.  Brief but efficient: acute HIV infection and the sexual transmission of HIV. , 2004, The Journal of infectious diseases.

[27]  M. Wainberg,et al.  Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. , 2004, The new microbiologica.

[28]  Stéphane Hué,et al.  HIV-1 pol gene variation is sufficient for reconstruction of transmissions in the era of antiretroviral therapy , 2004, AIDS.

[29]  F. Clavel,et al.  HIV Drug Resistance , 2000, The New England journal of medicine.

[30]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[31]  J. Church,et al.  ANTIRETROVIRAL-DRUG RESISTANCE AMONG PATIENTS RECENTLY INFECTED WITH HIV , 2003, Pediatrics.

[32]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[33]  F. van Griensven,et al.  Genetic analysis of incident HIV-1 strains among injection drug users in Bangkok: evidence for multiple transmission clusters during a period of high incidence. , 2002, Journal of acquired immune deficiency syndromes.

[34]  V. Soriano,et al.  Genetic mechanisms of resistance to NRTI and NNRTI , 2002, HIV clinical trials.

[35]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[36]  M. Uhlén,et al.  Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Stockman Estimation of HIV incidence in the United States , 2010 .

[38]  T. A. Hall,et al.  BIOEDIT: A USER-FRIENDLY BIOLOGICAL SEQUENCE ALIGNMENT EDITOR AND ANALYSIS PROGRAM FOR WINDOWS 95/98/ NT , 1999 .